AWS launches Amazon Bio Discovery to help researchers find drug candidates faster

AWS launched Amazon Bio Discovery, an AI tool that lets researchers design drug molecules and run computational workflows without writing code. A test with Memorial Sloan Kettering compressed months of antibody research into weeks.

Categorized in: AI News Healthcare
Published on: Apr 15, 2026
AWS launches Amazon Bio Discovery to help researchers find drug candidates faster

Amazon launches AI tool to compress drug discovery timelines

Amazon Web Services on Tuesday unveiled Amazon Bio Discovery, an AI application designed to accelerate early-stage drug discovery by allowing researchers to run complex computational workflows without writing code.

The platform gives scientists access to specialized biological foundation models that generate and evaluate potential drug molecules. An AI agent helps users select models, adjust parameters, and interpret results. Researchers can then send shortlisted candidates to integrated lab partners for synthesis and testing, with results fed back into the system to guide the next design cycle.

Addressing a computational bottleneck

The rise of drug-discovery models has created a constraint: computational biologists who can translate lab goals into machine-learning pipelines have become scarce. Rajiv Chopra, vice president of healthcare AI and life sciences at AWS, said the new tool addresses this gap.

In a collaboration with Memorial Sloan Kettering Cancer Center, the platform used multiple models to generate nearly 300,000 novel antibody molecules and narrow them to 100,000 candidates for lab testing. Work that typically takes months compressed into weeks.

Early adoption across pharma

Bayer, the Broad Institute, and Voyager Therapeutics are among the first adopters. AWS noted that 19 of the top 20 global pharmaceutical companies already use its cloud services.

Chopra said the service is designed to augment scientists and contract research organizations, not replace them. Jefferies analyst Tycho Peterson added that concerns about AI reducing demand for research instruments are overstated, with spending likely to increase as research pace and returns improve.

Clinical trial bottleneck next

AWS, Boston Consulting Group, and Merck will unveil a separate AI platform at AWS's Life Science Symposium aimed at improving clinical trial site selection-another common constraint in drug development.

For more on AI for Healthcare and AI for Science & Research, explore related resources.


Get Daily AI News

Your membership also unlocks:

700+ AI Courses
700+ Certifications
Personalized AI Learning Plan
6500+ AI Tools (no Ads)
Daily AI News by job industry (no Ads)